TP53 and neoplasm: To this end, we conducted CRISPR/Cas9 whole-genome screens to identify novel genes that mediate TRP53-tumour suppressive responses in murine Eμ-Myc lymphoma cells, a well-established model of aggressive B cell lymphoma [13].